TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 654409

Group type: EXPERIMENTAL
Intervention: Orciprenalin (0.1 mg/kg bodyweight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dopamine (0.5 mg)
Number of subjects: 10
Study: 31805025

Group type: EXPERIMENTAL
Intervention: Tailored Rehabilitation Education (TRE) program for 4 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no TRE program)
Number of subjects: 99
Study: 30536117

Group type: EXPERIMENTAL
Intervention: Intracervical Foley balloon catheter insertion adjunct to intravaginal PgE2 insert (n = 146)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Intravaginal PgE2 vaginal insert alone (n = 148)
Number of subjects: 294
Study: 28139456

Group type: EXPERIMENTAL
Intervention: Deferred Stenting (DS)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Immediate Stenting (IS)
Number of subjects: 258
Study: 26217468

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgery (CAS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 57
Study: 23286418

Group type: EXPERIMENTAL
Intervention: Karate competitors (KC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Exercise control (EC)
Number of subjects: 84
Study: 21472103

Group type: EXPERIMENTAL
Intervention: Diosmin 500 mg for 1 week
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19597718

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 191

Group type: COMPARATOR
Intervention: Monarc
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 191
Study: 16682681

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (without voglibose)
Number of subjects: 48
Study: 15139251

Group type: COMPARATOR
Intervention: Placebo as a comparative alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical arguments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resolution of moral conflicts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedural safeguards
Number of subjects: 0
Study: 11210397

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg tablet
Number of subjects: 7
Study: 9256875

Group type: EXPERIMENTAL
Intervention: Father-focused discussion perinatal classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional childbirth classes
Number of subjects: 0
Study: 8185742

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine i.v.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine i.v. + 10 mg metoclopramide i.v.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: 20 ml 0.3 M sodium citrate p.o.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: 20 ml 0.3 M sodium citrate p.o. + 10 mg metoclopramide i.v.
Number of subjects: 426
Study: 3037863

Group type: EXPERIMENTAL
Intervention: Dihydrotachysterol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 50
Study: 31262189

Group type: EXPERIMENTAL
Intervention: nifedipine+phytosterol
Number of subjects: 253

Group type: COMPARATOR
Intervention: nifedipine+placebo
Number of subjects: 253
Study: 28488912

Group type: EXPERIMENTAL
Intervention: High ER activity profile (10.5% of patients)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Tamoxifen or letrozole treatment
Number of subjects: 969
Study: 25944283

Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 week of age
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 month of age
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gut microbiome analysis at 1 year of age
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maternal gut microbiome analysis
Number of subjects: 20
Study: 23535978

Group type: EXPERIMENTAL
Intervention: Stereotype threat condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nullified-stereotype condition
Number of subjects: 40
Study: 21525688

Group type: EXPERIMENTAL
Intervention: PRP mixed with β‐TCP
Number of subjects: 20

Group type: COMPARATOR
Intervention: β‐TCP alone
Number of subjects: 20
Study: 18029218

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 16439507

Group type: EXPERIMENTAL
Intervention: GnRH agonist (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: HCG (n = 13)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 28

Group type: COMPARATOR
Intervention: HCG
Number of subjects: 28
Study: 14722348

Group type: EXPERIMENTAL
Intervention: Aggregated locomotor function (ALF) score
Number of subjects: 214
Study: 11284801

Group type: EXPERIMENTAL
Intervention: Sustained smokers
Number of subjects: 734

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 734
Study: 9133992

Group type: EXPERIMENTAL
Intervention: Protamine reversal of heparin
Number of subjects: 64

Group type: COMPARATOR
Intervention: No reversal of heparin
Number of subjects: 64
Study: 7958040

Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2844340

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune plasma (200 mg/kg body weight, given on four occasions during 2 days from day 3 to day 76 after transplantation)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune plasma
Number of subjects: 54
Study: 28885510

Group type: EXPERIMENTAL
Intervention: PD with pylorus preservation (PP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: PD with pylorus resection (PR)
Number of subjects: 188
Study: 27642131

Group type: EXPERIMENTAL
Intervention: Single-dose antihelminthic treatment (albendazole)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 25176152

Group type: EXPERIMENTAL
Intervention: AccuVein
Number of subjects: 266

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 266
Study: 23343840

Group type: EXPERIMENTAL
Intervention: Simulation with characteristic smoke and odor (intervention group, n = 52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No smoke or odor (control group, n = 51)
Number of subjects: 103
Study: 20089082

Group type: EXPERIMENTAL
Intervention: Tandospirone citrate (TC) 30 mg/day for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study: 18759315

Group type: EXPERIMENTAL
Intervention: Exercise treatment (specialized hands-on exercise training with muscle strengthening)
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 1234
Study: 12643400

Group type: EXPERIMENTAL
Intervention: Beating heart surgery with RVAD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beating heart surgery (off-pump)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional surgery with CPB
Number of subjects: 60
Study: 9672516

Group type: EXPERIMENTAL
Intervention: Theophylline/furosemide on day 1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo/furosemide on day 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline enhancement of furosemide's effect
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Renal function
Number of subjects: 24
Study: 8040776

Group type: EXPERIMENTAL
Intervention: Vancomycin added to parenteral alimentation solution (25 micrograms per milliliter)
Number of subjects: 70
Study: 2567667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beta-blockers (propranolol, metoprolol, oxprenolol)
Number of subjects: 8
Study: 1116100

Group type: COMPARATOR
Intervention: megavoltage extended field radiotherapy alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: megavoltage radiotherapy limited to involved lymph node sites followed by combination chemotherapy (MOPP)
Number of subjects: 87
Study: 31653157

Group type: EXPERIMENTAL
Intervention: Lymphedema prevention protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 120
Study: 28279499

Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5, 10, 20, or 40mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil (40mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil (20mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25692792

Group type: EXPERIMENTAL
Intervention: Zagreb regimen (4 doses/3 visits) of purified chick embryo cell vaccine (PCECV)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Essen regimen (5 doses over 5 days) of purified chick embryo cell vaccine (PCECV)
Number of subjects: 250
Study: 24019046

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 45
Study: 21664298

Group type: EXPERIMENTAL
Intervention: health maintenance intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 392
Study: 19268303

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 5300

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 5300

Group type: EXPERIMENTAL
Intervention: Cochrane Library systematic reviews
Number of subjects: 5300
Study: 16959055

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS over the right prefrontal cortex
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 2-Hz rTMS over the right prefrontal cortex
Number of subjects: 130

Group type: COMPARATOR
Intervention: 5-Hz left PFC rTMS
Number of subjects: 130

Group type: COMPARATOR
Intervention: 10-Hz left PFC rTMS
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 130
Study: 15106887

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Systemic‐behavioral-family therapy (SBFT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non‐directive‐supportive therapy (NST)
Number of subjects: 107
Study: 10837944

Group type: EXPERIMENTAL
Intervention: 4 months of goserelin and flutamide
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Long-term hormonal therapy
Number of subjects: 2200
Study: 9024957

Group type: EXPERIMENTAL
Intervention: 400 mg sodium valproate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 800 mg sodium valproate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8345158

Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 30136633

Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 105

Group type: COMPARATOR
Intervention: csDMARDs
Number of subjects: 105
Study: 29736609

Group type: COMPARATOR
Intervention: Standard prophylaxis (ciprofloxacin 500 mg B.I.D for 3 days)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Augmented prophylaxis (ciprofloxacin + single preprocedure shot of 160 mg gentamicin IM)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Targeted prophylaxis (rectal swab culture-based)
Number of subjects: 496
Study: 26183465

Group type: EXPERIMENTAL
Intervention: Uterine artery embolisation (UAE) with Gelfoam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uterine artery embolisation (UAE) with Embospheres
Number of subjects: 20
Study: 25162447

Group type: EXPERIMENTAL
Intervention: Combination treatment of Sertraline, Mianserin, psycho-education, and Trauma-Focused Cognitive Behavioral Therapy (TFCBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication (antidepressants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 22569999

Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: HIV positive individuals with poor ProM
Number of subjects: 160

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 160
Study: 20724806

Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment initiation within 24 hours (early group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Antiplatelet treatment initiation more than 24 hours (late group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 18482124

Group type: EXPERIMENTAL
Intervention: Diabetes Specialist Nurse prescriber intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pre-intervention group (control)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Post-intervention group (intervention)
Number of subjects: 56
Study: 16517540

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 37

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 37
Study: 12709518

Group type: EXPERIMENTAL
Intervention: Residency within 150-200 m from the composting site
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Residency in the highest bioaerosol exposure (150-200 m)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Unexposed controls (residency >400-500 m from the site)
Number of subjects: 356
Study: 10921700

Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg b.i.d.)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no beta-blockade or antiarrhythmic drugs)
Number of subjects: 206
Study: 8659783

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane, Halothane, Sevoflurane at 0.5 MAC
Number of subjects: 24
Study: 1389826

Group type: EXPERIMENTAL
Intervention: Propofol infusion during surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methohexitone infusion during surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol infusion in ICU
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methohexitone infusion in ICU
Number of subjects: 44
Study: 4039433

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 150
Study: 31319970

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression
Number of subjects: 71

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lanreotide in limited disease (LD)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Observation in limited disease (LD)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lanreotide in extensive disease (ED)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Observation in extensive disease (ED)
Number of subjects: 71
Study: 29084439

Group type: EXPERIMENTAL
Intervention: Weight-related counseling during primary care visits
Number of subjects: 535
Study: 26955809

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy (15 fractions of 2.4 Gy combined with gemcitabine 1,000 mg/m² on days 1, 8, and 15)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy after resection (four cycles in arm B)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Direct explorative laparotomy (control group)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy after resection (six cycles in arm A)
Number of subjects: 244
Study: 25267523

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 1,250 pulses/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study: 23146809

Group type: EXPERIMENTAL
Intervention: Psychological intervention and comprehensive rehabilitation training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard drug therapy, medical basic nursing, and conventional nursing)
Number of subjects: 120
Study: 19820080

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg (S50) bid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg (F250)/S50 bid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg (F100)/S50
Number of subjects: 39
Study: 18046673

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16242550

Group type: EXPERIMENTAL
Intervention: NGT removal at the time of tracheal extubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: NGT maintenance until the passage of flatus
Number of subjects: 40
Study: 12174789

Group type: EXPERIMENTAL
Intervention: Normal-dose ivermectin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose ivermectin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual ivermectin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-monthly ivermectin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: World Health Organization's African Programme for Onchocerciasis Control
Number of subjects: 0
Study: 10442366

Group type: EXPERIMENTAL
Intervention: UFT plus calcium folinate administered three times per day for 21 days in combination with paclitaxel
Number of subjects: 14
Study: 8553416

Group type: EXPERIMENTAL
Intervention: Suicide attempters
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Depressed/suicide ideators
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Nondepressed adolescents
Number of subjects: 1050
Study: 2150907

Group type: EXPERIMENTAL
Intervention: Trospectomycin sulfate (U‐63,366F) 1,000 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sterile saline (Control)
Number of subjects: 96
Study: 508127

Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to four 25-mg tablets per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31987547

Group type: EXPERIMENTAL
Intervention: Dance/Movement Training (DMT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 31004521

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy/Borkovec's treatment package
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy/Acceptance‐based behavioral therapy
Number of subjects: 75
Study: 28011248

Group type: EXPERIMENTAL
Intervention: 100% probability of receiving an antiemetic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 50% probability of receiving an antiemetic
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0% probability of receiving an antiemetic
Number of subjects: 48

Group type: COMPARATOR
Intervention: Inert substance (control for all groups)
Number of subjects: 48
Study: 24966147

Group type: EXPERIMENTAL
Intervention: Bolus group (levobupivacaine 0.5% every 6 h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous infusion group (levobupivacaine 0.25% at 5 ml/h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ANT with bolus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ANT with continuous infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: POST with bolus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: POST with continuous infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall (all cases)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ANT vs POST
Number of subjects: 80
Study: 23617259

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 80
Study: 21900585

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50,000 IU intravenous bolus prior to PPCI and another bolus 24 hours later (n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 51
Study: 18954400

Group type: EXPERIMENTAL
Intervention: Ultrasound and topical anesthetic
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham ultrasound and placebo anesthetic
Number of subjects: 100
Study: 16457894

Group type: EXPERIMENTAL
Intervention: STAR*D trial intervention strategies
Number of subjects: 4041

Group type: EXPERIMENTAL
Intervention: STAR*D trial ethical and procedural strategies
Number of subjects: 4041
Study: 12679945

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 135
Study: 10634454

Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride therapy, 5 mg/d for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 60
Study: 8957200

Group type: EXPERIMENTAL
Intervention: Multifactorial treatment programme (non-pharmacological treatment with possible drug therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 1382156

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study: 3553482

Group type: EXPERIMENTAL
Intervention: Amiloride + Salbutamol
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Amiloride + Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Salbutamol + Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Placebo + Placebo
Number of subjects: 118
Study: 31653884

Group type: EXPERIMENTAL
Intervention: New Corvis ST parameters in keratoconus eyes
Number of subjects: 154

Group type: COMPARATOR
Intervention: New Corvis ST parameters in normal eyes
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: ARTh and CBI
Number of subjects: 154
Study: 31324936

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3